Dynamic serological monitoring of COVID-19 vaccine response in immunocompromised populations
3 Dec 2021
Watch this presentation by Jeffrey Borgia, Director of Rush University Cancer Center Biorepository and Rush Biomarker Development Core, and Associate Professor, Department of Anatomy & Cell Biology, Rush Medical College, titled: Dynamic serological monitoring of COVID-19 vaccine response in immunocompromised populations. This talk was presented at the SelectScience® Virtual Biopharma Summit 2021.
About the company
Luminex
Luminex Corporation develops, manufactures, and sells proprietary technology, assays, and systems that empower labs to obtain reliable, timely, and actionable answers, ultimately advancing health. Our Molecular Diagnostics (MDx) and Life Science and Clinical Tools portfolios provide cost-effective, flexible solutions for hospitals, reference labs, and researchers, as well as innovative xMAP® and flow cytometry solutions that span a wide variety of applications, including molecular diagnostics, drug discovery, life science research, immunology, personalized medicine, cellular analysis, and more. Our goal is to transform global healthcare with innovative technology that delivers rapid, reliable results to clinicians and researchers. Most recently, we have been actively focused on providing diagnostic tests for SARS-CoV-2, with two diagnostic tests currently on the market. We are also pursuing several additional options in serology testing. For further information, please visit luminexcorp.com/.
Related products
Request Quote for All Products
xMAP® SARS-CoV-2 Multi-Antigen IgG Assay (RUO)
LuminexThe xMAP® SARS-CoV-2 Multi-Antigen IgG Assay is a serological, multiplexed microsphere-based assay to measure the presence of IgG antibodies directed against the nucleocapsid protein (N), Receptor-Binding Domain (RBD) of the spike protein, and the S1 subunit of the spike protein (S1) of SARS-CoV-2 in human serum or plasma. The xMAP SARS-CoV-2 Multi-Antigen IgG Assay features: Broad Coverage: Detects IgG antibodies against 3 SARS-CoV-2 antigens, providing comprehensive results: S1 subunit of the spike protein Receptor Binding Domain (RBD) of the spike protein Nucleocapsid protein Flexible Throughput: Test up to 96 samples per run in less than 3 hours to meet your throughput needs. Versatile System Options: Can be used on MAGPIX®, Luminex® 200™, and FLEXMAP 3D® Systems, so you can use the platform that best fits your lab. Common Sample Types: Designed for use with plasma and serum samples, eliminating the need to implement additional collection protocols. For Research Use Only. Not for use in diagnostic procedures.
